PL BioScience stands at the forefront of regenerative medicine, providing high-quality Human Platelet Lysate (HPL) solutions addressing critical challenges. PL BioScience’s ELAREM HPL technology is derived from human platelets and offers more reliable and standardized cell culture conditions than traditional cell culture media, including Fetal Bovine Serum (FBS). Animal-derived supplements are inconsistent, raise ethical concerns, and pose contamination risks, hindering the development of safe, effective cell therapies. HPL, which better mimics the physiological environment, is essential for aligning cell culture with physiological relevance, resulting in more reliable drug testing responses.

ELAREM HPL meets the evolving demands and regulatory standards of modern cell culture practices, especially in sensitive applications. As advancements in regenerative medicine drive the development of manufacturing facilities and regulatory frameworks, the demand for cell culture media is rapidly increasing. This trend is not only noticeable in Europe and the US, but also in China, where the HPL demand is growing quickly. Recognizing PL BioScience’s potential in these expanding markets, an international consortium, including Brightlands Venture Partners, recently provided a notable funding of € 7.8 million. This Series A financing brings together an experienced group of existing and new investors with a strong presence in Europe, the US and Asia, reflecting the confidence in the ELAREM technology.